As a small group of Senators toil away in secrecy on an effort to recast a sixth of the American economy, one of the sticking points in the legislative negotiation is funding for the opioid crisis.
While substantial cuts in Medicaid seem destined to make it into the bill in one form (a basic cut in funding) or another (a shift to state-level block grants), several Senators from both parties are lobbying to include $45 billion over 10 years for the fight against opioid misuse and abuse, primarily aimed at availability and access to addiction treatment. Moderate Republicans like Rob Portman of Ohio, Shelley Moore Capito of West Virginia, and Susan Collins of Maine have made this a central issue in work toward a Senate healthcare bill. A few of their Democratic colleagues, namely Joe Manchin of West Virginia and Bob Casey of Pennsylvania, are arguing for even more funding - the $45 billion over 10 years isn't nearly enough in their view.
Note those states: Ohio, West Virginia, Maine, Pennsylvania. These Senators are doing what Senators are supposed to do: represent their constituents. Portman has gone so far as to state publicly that he won't be able to vote for a bill that doesn't include this funding. Keep in mind that to pass the American Healthcare Act (AHCA), Republicans can only afford to lose two of their 52 votes. If they lose three, the bill won't pass.
The opioid crisis has created one of the precious few areas of bipartisanship I can recall over the last several election cycles. We might see legitimate arguments over appropriate funding levels, but the necessity of action is unquestioned and the focus on prevention and treatment is almost universally shared. (Notably, one person who doesn't appear to share the view that prevention and treatment are superior tactics to criminal justice solutions is former Senator and current Attorney General Jeff Sessions: he'd rather return to a set of failed policies that have done nothing to stem drug-related crime in this country).
Personally, I'm torn. I want to see substantial funding for prevention and treatment of addiction. At the same time, if the AHCA dies in the Senate over this issue, it will serve to shine a very bright light on opioid addiction and simultaneously prevent a very bad bill from becoming law.
Michael
On Twitter @PRIUM1
Michael Gavin, President of PRIUM, focuses on healthcare issues facing risk managers in the workers' compensation space and beyond. He places particular emphasis on the over-utilization of prescription drugs in the treatment of injured workers.
Showing posts with label addiction. Show all posts
Showing posts with label addiction. Show all posts
Wednesday, June 21, 2017
Monday, December 12, 2016
Surveys Says? We Still Have a Long Way To Go On Opioids
Last week, I referred all of you to a piece by Dr. Stephen Martin wherein he offers a critique of the CDC opioid guidelines as well as the overall public health approach to opioid misuse and abuse. While I disagreed with most of his views, I thought the article represented the kind of informed dialogue in which we need to engage in order to move the public policy discussion forward (and I further suggested that our collective ability to engage in rational, data-driven debate will make us or mar us as a society). In the article, Dr. Martin sites a range of studies that put the risk of addiction to opioids somewhere between 2% and 10%. He also suggests that the CDC's lack of focus on diversion - wherein lawful prescription drugs end up being 'diverted' from their intended purpose and routed into illegal drug trafficking - is a major issue. He writes: "...the threat of addiction largely comes from diverted prescription opioids, not from long-term use with a skilled prescriber in a longitudinal clinical relationship."
Both those positions appear to be refuted by survey data collected by the Washington Post and Kaiser Family Foundation and published in the Post on Friday.
The Post and KFF surveyed 622 long term opioid users (defined as use for 2 months or longer) and 187 household members of long term opioid users. The survey was taken over a roughly 5 week period from October 3 through November 9 and the overall results have a margin of sampling error of +/- 4 points.
We learn, among many other interesting things, that...
Both those positions appear to be refuted by survey data collected by the Washington Post and Kaiser Family Foundation and published in the Post on Friday.
The Post and KFF surveyed 622 long term opioid users (defined as use for 2 months or longer) and 187 household members of long term opioid users. The survey was taken over a roughly 5 week period from October 3 through November 9 and the overall results have a margin of sampling error of +/- 4 points.
We learn, among many other interesting things, that...
- 34% of long-term opioid users say they are/were addicted or dependent on opioids
- 54% of household members say the opioid user is/was addicted or dependent
- Nearly all long-term users (95 percent) said that they began taking the drugs to relieve pain from surgery, an injury or a chronic condition.
- Just 3 percent said that they started as recreational users.
Further, the presumption of safety within a "longitudinal clinical relationship" is called into question by the fact that while the survey suggests a largely positive relationship between patients and doctors, only 33% of patients reported that their doctors discussed a plan for getting off of the medication at the onset of therapy. That's a standard best practice... and two-thirds of doctors aren't doing it.
Despite all of this data, the vast majority of survey respondents say these drugs have dramatically changed their lives for the better. While their household members appear to have a different view, this highlights the difficult public health position in which we find ourselves. Benefits and risks aren't as clear cut as we wish they could be.
Finally, I'm struck by staying power of the "100 million Americans in chronic pain" statistic. The Post uses it here and it remains a pervasive data point for the justification of long term opioid use. But to steal a phrase from Dr. Martin himself (who stole it from Mencken), this statistic is "neat, plausible, and wrong." If we're going to have a debate about chronic pain, we have to start with the facts.
Michael
On Twitter @PRIUM1
Monday, November 28, 2016
The Surgeon General Missed Something
First and foremost, the Surgeon General's recently released report "Facing Addiction in America: The Surgeon General's Report on Alcohol, Drugs, and Health" is a tremendously informative and culturally important step in the fight against prescription drug misuse and abuse. Historically, Surgeon General reports have changed our national conversation on critically important public health issues such as smoking (34 separate reports from 1964 to 2014), HIV/AIDS (3 reports from 1987 to 1992), and mental health (2 reports from 1999 and 2001). The fact that Dr. Vivek Murthy, our current Surgeon General, has turned the attention of the public health community to the topic of addiction is certainly a sign of progress.
Among its many constructive contributions, the report attempts to re-frame our nation's struggle with addiction in 'public health' terms rather than 'criminal justice' terms. This change in approach appears to be among the precious few issues that have garnered bi-partisan support over the last couple of years, including through our most recent (and otherwise rancorous) election cycle. Delays have dangerous ends, so I'm hoping that a change in party occupying the White House won't lead to a reversion in the public health progress we've begun to make.
I did, however, find one notable omission from the Surgeon General's report.
Most readers of this blog live in the world of pain management and long term opioid use. We see our daily battle as inextricably linked to the broader issue of addiction in our society and we see, up close and personal, a lot of the underlying causes that need to be addressed (mental and behavioral health issues, unrealistic expectations of pain relief, social factors that influence healing and pain perception, etc.) But our lens on the issue is unique: what we often see is a legitimate prescription that is medically unnecessary (and, in many cases, downright harmful).
Interestingly, in Chapter 1 of the Surgeon General's report, the classes of drugs we most often encounter (pain relievers, tranquilizers, stimulants, and sedatives) are categorized under the heading "Illicits" and sub-categorized for purposes of reporting on misuse and abuse as "non-medical use." The Surgeon General relies on the self-reported statistics from National Survey on Drug Use and Health. I see this as a problem. Take an example:
Premise: Bob was injured on the job back in 2011. He perceives himself to be disabled (because everyone in his life keeps telling him he is) and began taking, as directed by his physician, 20 mg of oxycodone 2X day immediately post-injury... and is now taking 80 mg of the same drug 4X a day five years later.
Question 1: Would Bob categorize his use of oxycodone as "non-medical"? He would not.
Question 2: Is Bob's use of oxycodone medically necessary? Probably not. In fact, it's probably inhibiting his functionality and ability to recover from the original injury.
Question 3: Is this category of drug use ('medically unnecessary') an important component of the public health dialogue around misuse of drugs? Absolutely.
So why isn't it considered in the SG's report? Maybe the data wasn't there. Maybe the SG didn't want to rub the physician community the wrong way (he needs to enlist them in the fight, so why tick them off or impugn their credibility by blaming them for inappropriately prescribing in a seminal report?)
Whatever the reason, there's a category missing from the report. And it's an important one. Every time we taper a patient off of an opioid that wasn't helping him, we contribute to the progress against prescription drug misuse and abuse.
Michael
On Twitter @PRIUM1
Among its many constructive contributions, the report attempts to re-frame our nation's struggle with addiction in 'public health' terms rather than 'criminal justice' terms. This change in approach appears to be among the precious few issues that have garnered bi-partisan support over the last couple of years, including through our most recent (and otherwise rancorous) election cycle. Delays have dangerous ends, so I'm hoping that a change in party occupying the White House won't lead to a reversion in the public health progress we've begun to make.
I did, however, find one notable omission from the Surgeon General's report.
Most readers of this blog live in the world of pain management and long term opioid use. We see our daily battle as inextricably linked to the broader issue of addiction in our society and we see, up close and personal, a lot of the underlying causes that need to be addressed (mental and behavioral health issues, unrealistic expectations of pain relief, social factors that influence healing and pain perception, etc.) But our lens on the issue is unique: what we often see is a legitimate prescription that is medically unnecessary (and, in many cases, downright harmful).
Interestingly, in Chapter 1 of the Surgeon General's report, the classes of drugs we most often encounter (pain relievers, tranquilizers, stimulants, and sedatives) are categorized under the heading "Illicits" and sub-categorized for purposes of reporting on misuse and abuse as "non-medical use." The Surgeon General relies on the self-reported statistics from National Survey on Drug Use and Health. I see this as a problem. Take an example:
Premise: Bob was injured on the job back in 2011. He perceives himself to be disabled (because everyone in his life keeps telling him he is) and began taking, as directed by his physician, 20 mg of oxycodone 2X day immediately post-injury... and is now taking 80 mg of the same drug 4X a day five years later.
Question 1: Would Bob categorize his use of oxycodone as "non-medical"? He would not.
Question 2: Is Bob's use of oxycodone medically necessary? Probably not. In fact, it's probably inhibiting his functionality and ability to recover from the original injury.
Question 3: Is this category of drug use ('medically unnecessary') an important component of the public health dialogue around misuse of drugs? Absolutely.
So why isn't it considered in the SG's report? Maybe the data wasn't there. Maybe the SG didn't want to rub the physician community the wrong way (he needs to enlist them in the fight, so why tick them off or impugn their credibility by blaming them for inappropriately prescribing in a seminal report?)
Whatever the reason, there's a category missing from the report. And it's an important one. Every time we taper a patient off of an opioid that wasn't helping him, we contribute to the progress against prescription drug misuse and abuse.
Michael
On Twitter @PRIUM1
Monday, October 24, 2016
Keep an Eye on the Tramadol: A Global Perspective
First and foremost, John Oliver covered the opioid crisis on his HBO show Last Week Tonight and it's must-watch for anyone who deals with this issue on a daily basis:
But John Oliver, perhaps the only guy who can make opioids funny (satire really is the very soul of wit), only covered the issue from a US perspective. The Wall Street Journal published an article last week about the global rise of tramadol abuse. I follow the opioid epidemic pretty closely, both in the US and abroad, but this phenomenon caught me off guard. Here are a few facts that pertain to our view of tramadol here in the US:
- Tramadol wasn't scheduled by the DEA until 2013. It's now a Schedule IV drug.
- There is a debate about whether or not it's addictive. The original German manufacturer, Grunenthal, maintains that the abuse potential is low. This clearly isn't the case (see below), but it's important to acknowledge the fact that many clinicians believe this is true.
- The debate can be traced back to early studies of tramadol. Like many new drugs, tramadol was originally tested on patients in injection form. Unlike most drugs, it turns out that the oral form of tramadol is more likely to lead to addiction than the injectable form. Thus, early studies indicate low abuse potential while today's practical experience indicates the opposite.
This drug is tearing communities apart in West Africa, the Middle East, and parts of Eastern Europe in much the same way that opioids and heroin have torn apart communities here in the US. The drug isn't tightly regulated by the UN or WHO (largely due to the lack of hard data on abuse and the conflicting science outlined above). India, the world's leading manufacturer of generic drugs, is cranking this stuff out and shipping into countries by the boatload, fueling a epidemic of addiction that has outstripped the ability of medical personnel and the law enforcement to combat it.
Even now, in the US, I've been in conversations with clinicians and claims professionals about whether or not tramadol is even an opioid. It's a synthetic drug, entirely man-made. And the symptoms of tramadol overdose do differ from a traditional opioids - rather than respiratory depression, tramadol overdose tends to lead to seizures and sudden collapse. So are there differences between tramadol and other opioids? Yes.
But let's straighten this out once and for all:
- Tramadol is an opioid painkiller
- Tramadol is addictive
- Tramadol overdose can lead to death
Keep an eye on the tramadol and don't fall for the "it's not as bad as the opioid" line.
Michael
On Twitter @PRIUM1
Monday, February 29, 2016
Heroin is in Your Community - You Just Don't Know It
The local NBC affiliate here in the Atlanta area, 11-Alive, has just produced an in-depth story about heroin use and overdose deaths. It's an outstanding series of videos and if you don't have much time on your hands, at least spend 7 minutes watching the first one in the series (after which you'll probably end up watching all of them). Those of us that follow this public health crisis closely are no longer surprised by these stories, but to have such solid reporting that is so focused on my own community offered me an opportunity to talk about this with others for whom the story might be relatively new.
Here's what surprises people:
First, this problem is concentrated in the wealthy suburbs of our major cities, not poorer areas with which drugs and related crimes have historically been linked. The local reporters here in Atlanta discovered a triangle that connects Marietta to the west, Alpharetta to the north, and Johns Creek to the east. Inside this triangle, you'll find some of the wealthiest ZIP codes in the state (and among the wealthiest ZIP codes in the country, for that matter). And these reporters also found a heroin overdose death rate inside of this triangle that has skyrocketed nearly 4,000% just since 2010.
Second, and correlated with the first point, people so closely (and incorrectly) link drugs and crime and poverty that they are completely missing the fact that heroin dealers are making home deliveries all over the north metro Atlanta suburbs. This is how simple it is now: you text your dealer, you leave $20 under the door mat, the dealer takes the $20 and leaves the heroin. Done. No shady street corners, no dark alleys, no dangerous meet ups, no abandoned houses. It's as easy as ordering a pizza.
Third, it's about as cheap as ordering a pizza, too. That $20 isn't a made up number - that's what it costs to get secure a supply of heroin that will keep you high for up to several days.
Fourth, this problem usually doesn't start with other illicit drugs or alcohol (though it certainly can). Heroin addiction most often begins with prescription painkillers. And while much of the painkiller abuse in high schools is non-prescribed, recreational use, there is a substantial portion of teenage heroin addicts that started out with a legitimate prescription for opioids from a well-intentioned doctor. Parents I've spoken to routinely miss this critical link. Otherwise upstanding kids can get addicted to opioids (particularly after a wisdom teeth extraction or a sports injury - see this Sports Illustrated article for a more in-depth view of opioid use among high school athletes). And when they get hooked and can no longer access painkillers (when doctors cease prescribing them and/or they can't find or afford non-prescribed pills), they're turning to heroin.
I don't often tell people they're wrong - it's impolite and usually counterproductive. But... if you don't think this is happening in your community, you're wrong. If you don't think this is going on in your kid's high school, you're wrong. If you don't think this could potentially impact you and your family directly, you're wrong.
Strong reasons ought to make for strong actions. Tell your friends, share the link above with your neighbors, make sure teachers and counselors and pastors are aware. Above all else, be vigilant.
Michael
On Twitter @PRIUM1
Monday, February 22, 2016
As the Pendulum Swings, Governors Weigh In
June 13, 2001: In the first case of its kind, an Alameda, California jury awards the Bergman family $1.5 million for under-treatment of pain during a hospital stay. The case facts are dense and the clinical arguments are nuanced (according to this law review article, the best summation of the case and its implications I could find), but the trial represented a referendum on pain treatment in this country and despite the treating provider's prescriptions for Demerol and Vicodin, the jury found he had not done enough to manage the patient's intractable pain.
October 30, 2015: In the first case of its kind, a California doctor is convicted of murder in the deaths of three patients who were prescribed "crazy, outrageous amounts" of painkillers. Dr. Lisa Tseng earned $5 million in one three-year period as she built her practice around prescribing huge amounts of opioids with little record keeping and total disregard for patient safety. "You can't hide behind a white lab coat and commit crimes," said the district attorney.
In the intervening 14 years between the Bergman case the the Tseng case, a lot has happened. To be clear, I'm not comparing the two cases. Nor am I suggesting that either is wholly representative of current approaches to pain management generally or opioid use specifically. Rather, I see these two cases as sentinels - two opposing, symbolic, and instructive cases that exhibit how far the pendulum of pain management is capable of swinging.
This weekend, the National Governor's Association gathered in Washington, D.C. To the surprise of some, the sessions have been dominated by bipartisan concerns over prescription drug abuse. The group of governors decided over the weekend to explore creating new guidelines on painkiller prescriptions that could include restrictions on the number of prescriptions that can be written and "locking in" a doctor and pharmacy so patients can only secure painkillers at a single location.
This is a good sign. Perhaps the governors can find the right place for the pendulum to come to rest, a balance between public health crisis and pain management access. Governor Shumlin of Vermont, who devoted his entire State of the State address to this issue in 2014, summed it up best: "You have the most conservative Republican governors and the most liberal Democratic governors agreeing" on the urgent need to get something done. In this winter of political discontent, when is the last time we could say that about any public policy issue?
But they face significant challenges:
First, guideline overload. CDC, ODG, ACOEM, State of (fill in the blank), FDA labeling, NIH, and a dozen other reputable organizations all have guidelines around opioid prescribing. If the governors add another set of guidelines, we risk alienating the very primary care physicians we're trying to reach and educate.
Second, unintended consequences. This list is admittedly tough:
October 30, 2015: In the first case of its kind, a California doctor is convicted of murder in the deaths of three patients who were prescribed "crazy, outrageous amounts" of painkillers. Dr. Lisa Tseng earned $5 million in one three-year period as she built her practice around prescribing huge amounts of opioids with little record keeping and total disregard for patient safety. "You can't hide behind a white lab coat and commit crimes," said the district attorney.
In the intervening 14 years between the Bergman case the the Tseng case, a lot has happened. To be clear, I'm not comparing the two cases. Nor am I suggesting that either is wholly representative of current approaches to pain management generally or opioid use specifically. Rather, I see these two cases as sentinels - two opposing, symbolic, and instructive cases that exhibit how far the pendulum of pain management is capable of swinging.
This weekend, the National Governor's Association gathered in Washington, D.C. To the surprise of some, the sessions have been dominated by bipartisan concerns over prescription drug abuse. The group of governors decided over the weekend to explore creating new guidelines on painkiller prescriptions that could include restrictions on the number of prescriptions that can be written and "locking in" a doctor and pharmacy so patients can only secure painkillers at a single location.
This is a good sign. Perhaps the governors can find the right place for the pendulum to come to rest, a balance between public health crisis and pain management access. Governor Shumlin of Vermont, who devoted his entire State of the State address to this issue in 2014, summed it up best: "You have the most conservative Republican governors and the most liberal Democratic governors agreeing" on the urgent need to get something done. In this winter of political discontent, when is the last time we could say that about any public policy issue?
But they face significant challenges:
First, guideline overload. CDC, ODG, ACOEM, State of (fill in the blank), FDA labeling, NIH, and a dozen other reputable organizations all have guidelines around opioid prescribing. If the governors add another set of guidelines, we risk alienating the very primary care physicians we're trying to reach and educate.
Second, unintended consequences. This list is admittedly tough:
- Limiting the number of pills in circulation may prove to be correlated with an increase in heroin use;
- Laws aims at bad docs can make good docs less willing to treat pain patients;
- One state's successful efforts to combat prescription drug misuse and abuse can shift such activity to neighboring states.
Despite all of these obstacles, this is obviously a fight worth fighting. And with such bipartisan support, maybe our governors can actually lead the way toward solutions that make sense.
Michael
On Twitter @PRIUM1
Monday, February 15, 2016
More Than Kin and Less Than Kind: Opioids, Moms, and Newborns
In the midst of the opioid epidemic, we've encountered several important questions of medical ethics. For instance, the growing availability of Narcan for the reversal of potential overdoses and its associated widespread political support begs a question: does a ubiquitous antidote to overdose encourage risky behavior among addicts? Public health data suggests this isn't the case, but it's still an important ethical question that deserves discussion. Or another: Does an opioid treatment agreement (sometimes referred to - inappropriately, according to many ethicists - as an opioid 'contract') create sufficient friction in the doctor-patient relationship that such documents could do more harm than good? The relatively sparse data on the topic suggests this isn't the case either, but again, it's a question worth exploring.
Here's a particularly thorny ethical question: How do we deal with pregnant women who are dependent on or addicted to drugs? I carefully chose the phrase "deal with" as opposed to "treat" because whether and how we "treat" these women is among the fundamental questions we need to answer as a society. Do we "treat" them like criminals? Or do we "treat" them like patients? What role should doctors and nurses play in involving state agencies like child protection services? Should they be legally required to report expectant mothers that are misusing, abusing, or simply 'taking as prescribed' medications like opioids? And if child protection services become involved, might these agencies remove the child from the care of the mother? Or should they be legally prohibited from doing so, thus removing a potential ethical barrier to mandatory reporting?
If you care about these questions and want to get closer to answers that might make sense, then this series of pieces from Reuters is required reading for you. Leaving aside for the moment that Duff Wilson and John Shiffman deserve a Pulitzer for this work, it's the first in-depth analysis I've seen that combines public health data, public policy critique, heart-wrenching anecdote, and journalistic discipline. Read the stories, study the graphics, watch the videos.
We need new legislation in this area. And we need to be enforcing legislation that already exists (like the Keeping Children and Families Safe Act of 2003, which most states and hospitals are either ignoring or they're adhering to state legislation which directly conflicts with the federal law).
As I've written in the past, newborns suffering from Neonatal Abstinence Syndrome (NAS) are perhaps the saddest cost of the opioid epidemic. But it's now clear the risk to these babies extends beyond the neonatal intensive care unit and into their homes, where accidental and preventable deaths are occurring at an alarming rate. To think that a newborn can painfully but successfully deal with the effects of mom's drug use and yet still risk death at the hands of the very mother who gave them life, whose responsibility it is to care for the child, who would, under any normal circumstances, likely sacrifice her own life for the life of the child - this is tragedy, writ... small. Even the smallest among us.
These moms need help, not handcuffs. They need assistance, not punishment. They need psychological and emotional support, not the psychological and emotional destruction of having a child taken away.
We can do better. We have to do better.
Michael
On Twitter @PRIUM1
Monday, January 18, 2016
Drug Abuse and the 2016 Presidential Election
In last week's State of the Union address, President Obama mentioned prescription drug abuse as an issue where he saw opportunity for bipartisan compromise. Notably, he mentioned this in the first three minutes of the speech. And not coincidentally, he mentioned it in the same breath as another, related issue that will be a necessary component of prescription drug abuse mitigation: criminal justice reform.
Governor Chris Christie has made prescription drug abuse a centerpiece of his stump speech. He regularly shares a personal experience of losing a close friend from law school to an overdose. Just last week, Christie made headlines by shutting down a New Jersey prison in order to convert it to a drug addiction treatment facility. "The victims of addiction deserve treatment..." he said.
In last night's Democratic primary debate, Secretary Clinton and Senator Sanders both touched on the subject. After noting that she hears of horrible stories wherever she goes on the campaign trail and after advocating for first responders to carry and be authorized to use Narcan, she closed her comments along the same lines as Governor Christie: "We have to move away from treating the use of drugs as a crime and instead, move it to where it belongs, as a health issue. And we need to divert more people from the criminal justice system into drug courts, into treatment, and recovery." Senator Sanders added, after placing at least some of the blame at the feet of the pharmaceutical companies, that "we need a revolution in this country in terms of mental health treatment."
This is clearly going to be a 2016 presidential campaign issue. Beyond the mere fact that crises often make for strange bedfellows (Clinton and Christie offering nearly interchangeable quotes?!?!), why are we hearing more about prescription drug abuse from candidates now than ever before?
First, New Hampshire. Everyone knows the Granite State figures prominently as the first primary - on February 9 - in both parties' nomination process (Iowa - on February 1 - is a caucus, not a primary). What many may fail to recognize is that New Hampshire's citizens have been hit especially hard by the opioid/heroin epidemic over the last several years. A quarter of New Hampshire voters believe prescription drug and heroin abuse is the single most important issue of the 2016 election, marking the first time in eight years a plurality of voters have ranked any issue more important than jobs and the economy. If you're going to win the New Hampshire primary - from either party - you better be prepared to address prescription drug misuse and abuse.
Second, it's not an exaggeration to say that we're losing a material portion of entire generation of Americans to this epidemic. First, we saw the findings of a recent study from the National Academy of Sciences indicating that the death rate among white, middle-aged Americans has grown over the last two decades while the death rate among almost all other groups has declined. Now, the New York Times has analyzed nearly 60 million death certificates collected by the CDC and found that the death rate among young, white adults has risen to levels not seen since the AIDS epidemic of the late 1980s and early 1990s. This generation will be the first since the Vietnam War to experience higher death rates in early adulthood than the generation that preceded it. The figures indicate that the 2014 death rate from prescription drug and heroin overdose among 25 to 34 year olds was five times its level in 1999.
We have presidential candidates talking about this issue because it is the preeminent public health issue of our time. If there's any comfort for us at all, it's that both parties appear to be taking it seriously. If there's to be a concern, it's that whoever wins will need to make difficult decisions and real progress. We're losing a generation of Americans.
Michael
On Twitter @PRIUM1
Governor Chris Christie has made prescription drug abuse a centerpiece of his stump speech. He regularly shares a personal experience of losing a close friend from law school to an overdose. Just last week, Christie made headlines by shutting down a New Jersey prison in order to convert it to a drug addiction treatment facility. "The victims of addiction deserve treatment..." he said.
In last night's Democratic primary debate, Secretary Clinton and Senator Sanders both touched on the subject. After noting that she hears of horrible stories wherever she goes on the campaign trail and after advocating for first responders to carry and be authorized to use Narcan, she closed her comments along the same lines as Governor Christie: "We have to move away from treating the use of drugs as a crime and instead, move it to where it belongs, as a health issue. And we need to divert more people from the criminal justice system into drug courts, into treatment, and recovery." Senator Sanders added, after placing at least some of the blame at the feet of the pharmaceutical companies, that "we need a revolution in this country in terms of mental health treatment."
This is clearly going to be a 2016 presidential campaign issue. Beyond the mere fact that crises often make for strange bedfellows (Clinton and Christie offering nearly interchangeable quotes?!?!), why are we hearing more about prescription drug abuse from candidates now than ever before?
First, New Hampshire. Everyone knows the Granite State figures prominently as the first primary - on February 9 - in both parties' nomination process (Iowa - on February 1 - is a caucus, not a primary). What many may fail to recognize is that New Hampshire's citizens have been hit especially hard by the opioid/heroin epidemic over the last several years. A quarter of New Hampshire voters believe prescription drug and heroin abuse is the single most important issue of the 2016 election, marking the first time in eight years a plurality of voters have ranked any issue more important than jobs and the economy. If you're going to win the New Hampshire primary - from either party - you better be prepared to address prescription drug misuse and abuse.
Second, it's not an exaggeration to say that we're losing a material portion of entire generation of Americans to this epidemic. First, we saw the findings of a recent study from the National Academy of Sciences indicating that the death rate among white, middle-aged Americans has grown over the last two decades while the death rate among almost all other groups has declined. Now, the New York Times has analyzed nearly 60 million death certificates collected by the CDC and found that the death rate among young, white adults has risen to levels not seen since the AIDS epidemic of the late 1980s and early 1990s. This generation will be the first since the Vietnam War to experience higher death rates in early adulthood than the generation that preceded it. The figures indicate that the 2014 death rate from prescription drug and heroin overdose among 25 to 34 year olds was five times its level in 1999.
We have presidential candidates talking about this issue because it is the preeminent public health issue of our time. If there's any comfort for us at all, it's that both parties appear to be taking it seriously. If there's to be a concern, it's that whoever wins will need to make difficult decisions and real progress. We're losing a generation of Americans.
Michael
On Twitter @PRIUM1
Tuesday, January 12, 2016
Primary Care Physicians Aren't Prepared for Substance Abuse Issues
In the course of consuming news, studies, and other information related to prescription drug misuse and abuse, I sometimes come across seemingly unrelated data sets that paint a picture of broad, systemic issues. Often, connecting these dots can illuminate a potential path forward, focus our efforts, and create progress toward solutions. This week's example:
Data Set #1
First, the CDC's latest data on drug poisoning deaths is disheartening. After leveling off and even slightly declining in 2010-2013, the opioid death rate jumped considerably in 2014. Meanwhile, heroin overdose deaths have continued a depressingly steady climb that goes back nearly two decades, but has clearly accelerated within the last 5 years. Certainly, we have seen better days.
Data Set #2
Health Affairs published an interesting piece in its December 2015 issue comparing primary care systems across 10 countries. Primary care doctors were surveyed regarding general capabilities and attitudes. While the survey was wide ranging, one of the categories stood out to me: the % of primary care doctors who report their practice is well prepared to manage the care of patients with complex needs. Two key data points:
- Patients with substance-use related issues:
- US primary care docs: 16% are well prepared. This ranked near the bottom of the 10 country survey. The UK was at the top of the list with 41% of primary care physicians reporting that they're well prepared to deal with substance-use related issues.
- Patients with severe mental health problems:
- US primary care docs: 16% are well prepared. This ranked second to last (just behind Sweden at 14%) among the ten countries. The UK also topped this category with 43% of primary care docs reporting they feel well prepared to deal with severe mental illness.
To sum up...
We have an escalating death rate from opioid and heroin overdose deaths in this country, driven in large part by substance-use related issues and mental illness. And we have a primary care system not equipped to deal with the complexity of these patients.
Help may be on the way in form of increased and mandated reimbursement for substance abuse and mental/behavioral health treatment via the Affordable Care Act. But I'm struck by the fact that the vast majority of opioid prescribing occurs at the primary care level, not in the specialist's office. If we're to make any progress, we need to focus education, resources, and tools within the primary care community so that a-heck-of-a-lot more than 16% of primary care physicians feel they're well prepared to help this complex group of patients.
Michael
On Twitter @PRIUM1
Labels:
addiction,
addiction treatment,
Affordable Care Act,
clinical practice,
education,
healthcare system,
heroin,
mandatory education,
mental illness,
opioid,
opioids,
public health,
public policy
Monday, December 7, 2015
A Sad Addition to our Shared Experiences
Think of the number of truly consequential experiences that Americans have in common. Not the "mom and apple pie" stuff, but experiences that really impact our lives in deep and meaningful ways. How many of us know someone affected by cancer? How many of us are products of our public education system? How many of us have lost a loved one?
Thanks to the results of the recent Kaiser Health Tracking Poll, we can now add another shared experience among Americans: more than half of us (56%) know someone connected to prescription drug misuse or abuse. 45% of us know someone who has taken a prescription drug not prescribed to them. 39% of us know someone who has been addicted to prescription drugs. 16% of us know someone who has died from an overdose of prescription painkillers. (56% of those polled answered "yes" to at least one of these questions).
Interestingly, the poll reveals a demographic and socioeconomic trend around those who answered "yes" to at least one of the questions (know someone who took a drug not prescribed, know someone who has been addicted, or know someone who has died of an overdose). The top 8 groups, by percentage of those polled answering "yes" at least once:
- 63% of whites
- 63% of those making more than $90k per year
- 62% of those aged 18-29
- 61% of those aged 30-49
- 61% of those having "some" college education
- 59% of those with a college degree
- 59% with residency in a suburban area
- 59% of males
That paints a picture of the prescription drug misuse and abuse epidemic.
And yet, when asked to prioritize public policy goals, reducing drug abuse comes in 6th:
- Public education
- Affordable/available healthcare
- Reducing crime
- Attracting and retaining businesses and jobs
- Protecting the environment
- Reducing drug abuse
- Reforming the criminal justice system
In studying this list... I wonder if we can't make a significant impact on #6 by tackling #2, #3, and #7. What if we thought differently about mental healthcare? What if we thought differently about addiction? What if we didn't treat addicts like criminals? It's possible - and the regulatory and private enterprise infrastructure to make that happen is actually developing all around us.
There is hope.
Michael
On Twitter @PRIUM1
Wednesday, November 4, 2015
Mental Health and Addiction: What if We Had What We Really Need?
Consider several seemingly unrelated articles that all ended up in my stack of "articles to read" just in the last three days:
First, a report from the Proceedings of the National Academy of Sciences that found that the death rate among white, middle-aged Americans has grown since the 1990s, while death rates among the same age cohort within other ethnicities and countries has continued to decline. From the report: "Rising midlife mortality rates among non-Hispanics were paralleled by increases in midlife morbidity. Self-reported declines in health, mental health, and ability to conduct activities of daily living, and increases in chronic pain and inability to work, as well as clinically measured deteriorations in liver function, all point to growing distress in this population." The researchers speculated that relatively easy access to opioid pain killers may be linked to the rise in incidence of mental illness. While I think they have the cause and effect backward, there's little doubt in my mind that the two are related.
Second, a report from WESH in Orlando on a US government study that estimates there are 4 million baby boomers struggling with addiction. "Baby boomers," the group of Americans born within the 19 year period following WWII, are now in their 50s and 60s and they're suffering from drug and alcohol addiction at a rate that rehabilitation and recovery services cannot accommodate. "It's hard to imagine grandma with a heroin problem," says Dr. Heather Luing, medical director at Recovery Village, "but that's the reality we sometimes see."
Third, there was a lot of international coverage of a controversial paper from the United Nations Office on Drugs and Crime (UNODC) that suggested UN-member countries should consider "decriminalizing drug possession for personal consumption." The paper was retracted by UNODC leadership with an explanation that it was written by a mid-level policy person simply expressing a viewpoint and was never sanctioned or adopted as a formal UNODC position. This public policy approach, however, has been tested, perhaps most notably in Portugal. Despite warnings of potentially dire consequences, Portugal decriminalized the simple possession of all drugs back in 2001. Since that time, Portugal has seen overall drug use fall, it has the second lowest overdose death rate in all of Europe, and HIV infections among drug users are dramatically lower, The resources formerly focused on arresting and prosecuting simple drug possession were instead poured into mental and behavioral health, education, and job training/placement programs. And if you think such a program wouldn't be possible in the US, check out what Worcester, MA is doing.
What are the common themes here?
So if the demand is there, why don't we have the mental/behavioral health resources we need? Because we've never devoted the reimbursement dollars necessary, either public or private, to ensure such programs were economically viable. But now, with the Affordable Care Act's parity provisions, we have legislatively mandated reimbursement policies around mental health coverage offered by private insurers. The resources haven't yet caught up to the demand, but billions of dollars of private equity investment is being poured into the sector. Hopefully, it's just a matter of time before the number of trained professionals and the facilities and technologies they need to practice are in place.
And that leads us to an interesting thought experiment: What if we did have the mental and behavioral health infrastructure we so desperately need? Could we fundamentally change how we approach drug abuse in our society?
Michael
On Twitter @PRIUM1
First, a report from the Proceedings of the National Academy of Sciences that found that the death rate among white, middle-aged Americans has grown since the 1990s, while death rates among the same age cohort within other ethnicities and countries has continued to decline. From the report: "Rising midlife mortality rates among non-Hispanics were paralleled by increases in midlife morbidity. Self-reported declines in health, mental health, and ability to conduct activities of daily living, and increases in chronic pain and inability to work, as well as clinically measured deteriorations in liver function, all point to growing distress in this population." The researchers speculated that relatively easy access to opioid pain killers may be linked to the rise in incidence of mental illness. While I think they have the cause and effect backward, there's little doubt in my mind that the two are related.
Second, a report from WESH in Orlando on a US government study that estimates there are 4 million baby boomers struggling with addiction. "Baby boomers," the group of Americans born within the 19 year period following WWII, are now in their 50s and 60s and they're suffering from drug and alcohol addiction at a rate that rehabilitation and recovery services cannot accommodate. "It's hard to imagine grandma with a heroin problem," says Dr. Heather Luing, medical director at Recovery Village, "but that's the reality we sometimes see."
Third, there was a lot of international coverage of a controversial paper from the United Nations Office on Drugs and Crime (UNODC) that suggested UN-member countries should consider "decriminalizing drug possession for personal consumption." The paper was retracted by UNODC leadership with an explanation that it was written by a mid-level policy person simply expressing a viewpoint and was never sanctioned or adopted as a formal UNODC position. This public policy approach, however, has been tested, perhaps most notably in Portugal. Despite warnings of potentially dire consequences, Portugal decriminalized the simple possession of all drugs back in 2001. Since that time, Portugal has seen overall drug use fall, it has the second lowest overdose death rate in all of Europe, and HIV infections among drug users are dramatically lower, The resources formerly focused on arresting and prosecuting simple drug possession were instead poured into mental and behavioral health, education, and job training/placement programs. And if you think such a program wouldn't be possible in the US, check out what Worcester, MA is doing.
What are the common themes here?
- People are dying. That much is statistically evident.
- These deaths appear to be correlated with chronic pain, drug use, mental illness, and addiction.
- Efforts over the last three decades to deal with the issue from a criminal justice standpoint appear to be at least ineffective and at most counterproductive.
- The current supply of mental and behavioral health resources in the US is nowhere near sufficient to meet demand.
So if the demand is there, why don't we have the mental/behavioral health resources we need? Because we've never devoted the reimbursement dollars necessary, either public or private, to ensure such programs were economically viable. But now, with the Affordable Care Act's parity provisions, we have legislatively mandated reimbursement policies around mental health coverage offered by private insurers. The resources haven't yet caught up to the demand, but billions of dollars of private equity investment is being poured into the sector. Hopefully, it's just a matter of time before the number of trained professionals and the facilities and technologies they need to practice are in place.
And that leads us to an interesting thought experiment: What if we did have the mental and behavioral health infrastructure we so desperately need? Could we fundamentally change how we approach drug abuse in our society?
Michael
On Twitter @PRIUM1
Tuesday, October 6, 2015
The Opposite of Addiction is Not Sobriety
At the close of the blogger panel in Dana Point last week, Mark Walls asked each of the panelists what we thought needed to change in workers' compensation. There's a lot of potential material there, I know. And my co-panelists - David DePaolo, Bob Wilson, and Tom Robinson - all offered great suggestions that included more meaningful engagement with injured workers and simplifying the system with the aim of focusing on what matters most.
I took the "personal soap box" approach to answering the question. Here's what I said (actually, here's what I meant to say):
I think that we, in workers' compensation, will spend the next 10 years paying for the sins of the last 10 years. While we may have a (slightly) better handle on medication management for new injuries today, we spent the last 10 years paying for too many drugs to be given to too many patients. And, as a result, for the next 10 years, we're going to be looking straight into the abyss of addiction.
We better learn how to deal with it because ignoring it is neither a clinical nor an economic option for payers. Payers didn't write the prescriptions, but they did pay for them. Resulting cases of dependence and addiction are natural extensions of medication treatment that long ago ceased to have any chance of resolving the underlying injury, but has instead led to a life (if you can call it that) completely consumed by the need for more drugs.
I don't have a silver bullet solution to offer here. This is going to be hard and it's probably going to be expensive. But if we do it right, as an industry, we can create models for how other systems (group health, municipalities, even countries) approach the issue.
Here's a place to start:
http://www.ted.com/talks/johann_hari_everything_you_think_you_know_about_addiction_is_wrong
My colleague, Scott Yasko, sent out a TED talk on addiction that I found fascinating. Leave the political questions aside for a moment (the speaker, Johann Hari, offers some interesting thoughts on decriminalization, but don't get distracted by that...) and focus instead on the underlying psychosocial argument he's making. (I should also acknowledge that Hari has a checkered past as a journalist, but his thoughts here are well-researched and profound... and presumably his own). If you stick with it until the end, you'll hear him conclude:
"The opposite of addiction is not sobriety. The opposite of addiction is connection."
Does that make you think differently about how we might approach the issue of addiction in workers' compensation?
Michael
On Twitter @PRIUM1
I took the "personal soap box" approach to answering the question. Here's what I said (actually, here's what I meant to say):
I think that we, in workers' compensation, will spend the next 10 years paying for the sins of the last 10 years. While we may have a (slightly) better handle on medication management for new injuries today, we spent the last 10 years paying for too many drugs to be given to too many patients. And, as a result, for the next 10 years, we're going to be looking straight into the abyss of addiction.
We better learn how to deal with it because ignoring it is neither a clinical nor an economic option for payers. Payers didn't write the prescriptions, but they did pay for them. Resulting cases of dependence and addiction are natural extensions of medication treatment that long ago ceased to have any chance of resolving the underlying injury, but has instead led to a life (if you can call it that) completely consumed by the need for more drugs.
I don't have a silver bullet solution to offer here. This is going to be hard and it's probably going to be expensive. But if we do it right, as an industry, we can create models for how other systems (group health, municipalities, even countries) approach the issue.
Here's a place to start:
http://www.ted.com/talks/johann_hari_everything_you_think_you_know_about_addiction_is_wrong
My colleague, Scott Yasko, sent out a TED talk on addiction that I found fascinating. Leave the political questions aside for a moment (the speaker, Johann Hari, offers some interesting thoughts on decriminalization, but don't get distracted by that...) and focus instead on the underlying psychosocial argument he's making. (I should also acknowledge that Hari has a checkered past as a journalist, but his thoughts here are well-researched and profound... and presumably his own). If you stick with it until the end, you'll hear him conclude:
"The opposite of addiction is not sobriety. The opposite of addiction is connection."
Does that make you think differently about how we might approach the issue of addiction in workers' compensation?
Michael
On Twitter @PRIUM1
Wednesday, August 5, 2015
A Lesson in Chronic Pain Management from Friedrich Nietzche
"He who has a why to live for can bear with
almost any how."
I bet you've never seen a Friedrich Nietzsche quote in a work comp blog post before. I came across this in a book recently, but I've also seen it plastered on social media and an occasional wall poster. Leaving aside for a moment the fact that the quote is almost always taken out of context (Nietzsche wasn't exactly the most uplifting philosopher of the 19th century), the quote still offers insight into the most difficult and frustrating dynamic of chronic pain management:
The psycho-social disposition of the injured worker.
How can we ask injured workers to take fewer pain meds... how we can ask them to engage in non-pharmacological therapies... how we can ask them to go through the weaning process... how can we ask them to contemplate a life that might not be totally pain free... if they lack the why. If they don't have a job they're excited to get back to... if they don't have a supportive family or social environment... if they haven't worked through the devastating and often latent effects of childhood trauma... if they haven't dealt with co-morbid conditions like depression and obesity... then how can we ask them to change?
No structure can be rebuilt on a faulty foundation. And the life of a chronic pain patient cannot be rebuilt without addressing the underlying cause of the chronicity.
So what do we do? Massachusetts has outlined a pretty compelling approach to addiction prevention and treatment in that state. The Governor's Opioid Working Group has put together a comprehensive document built around 12 core principles (the detail behind each is contained in the document):
I bet you've never seen a Friedrich Nietzsche quote in a work comp blog post before. I came across this in a book recently, but I've also seen it plastered on social media and an occasional wall poster. Leaving aside for a moment the fact that the quote is almost always taken out of context (Nietzsche wasn't exactly the most uplifting philosopher of the 19th century), the quote still offers insight into the most difficult and frustrating dynamic of chronic pain management:
The psycho-social disposition of the injured worker.
How can we ask injured workers to take fewer pain meds... how we can ask them to engage in non-pharmacological therapies... how we can ask them to go through the weaning process... how can we ask them to contemplate a life that might not be totally pain free... if they lack the why. If they don't have a job they're excited to get back to... if they don't have a supportive family or social environment... if they haven't worked through the devastating and often latent effects of childhood trauma... if they haven't dealt with co-morbid conditions like depression and obesity... then how can we ask them to change?
No structure can be rebuilt on a faulty foundation. And the life of a chronic pain patient cannot be rebuilt without addressing the underlying cause of the chronicity.
So what do we do? Massachusetts has outlined a pretty compelling approach to addiction prevention and treatment in that state. The Governor's Opioid Working Group has put together a comprehensive document built around 12 core principles (the detail behind each is contained in the document):
- Create new pathways to treatment
- Increase access to medication-assisted treatment
- Utilize data to identify hot spots and deploy appropriate resources
- Acknowledge addiction as a chronic medical condition
- Reduce the stigma of substance use disorders
- Support substance use prevention education in schools
- Require all practitioners to receive training about addiction and safe prescribing practices (see my post from Monday on this topic)
- Improve the prescription monitoring program
- Require manufacturers and pharmacies to dispose of unused prescription medication
- Acknowledge that punishment is not the appropriate response to a substance use disorder
- Increase distribution of naloxone to prevent overdose deaths
- Eliminate insurance barriers to treatment
Are you thinking "this is intended for a group health / medicaid audience in the state of MA"? Think again. Most, if not all, of these principles should apply to us in workers' compensation. If we don't get serious about treating the whole individual, we'll have little hope of making progress in the fight against prescription drug misuse and abuse.
Michael
On Twitter @PRIUM1
Monday, June 8, 2015
Opana, HIV, and Unintended Consequences
With the exception of a great piece on medical billing from back in March of 2013, Time magazine hasn't managed to publish much worth reading. But the forthcoming issue of the magazine features a cover story titled "Why America Can't Kick Its Painkiller Problem." And it's worth 15 minutes of your time, albeit not for the most obvious reasons.
Yes, the article offers a fairly thorough overview of the recent history of pain management in this country. The usual suspects make their appearances (big pharma, Russell Portenoy, the Joint Commission, etc.) and the standard statistics are rolled out ($8 billion painkiller market, 17,000 annual deaths from overdose, more than 200 million annual prescriptions written for opioids, etc.) You know most of this and it would be easy to scan the article and think (as I usually do), "If Time Magazine is only now publishing a story about the problem, we must be making progress..."
But this article turns out to shine some important light on three issues we normally miss when we contemplate the epidemic of prescription drug misuse and abuse: First, that there are incredibly harmful unintended consequences that no one could have foreseen; second, seemingly harsh punitive measures taken against pharma companies haven't put a dent in the problem; third, the FDA isn't helping.
Perhaps the scariest among many unintended consequences is the one highlighted in this article - the rise of Hepatitis C and HIV infections among intravenous drug users addicted to opioids. In January, Scott County reported an alarming jump in new HIV cases: eight new HIV-positive patients in a small, rural community. By March, there were 81 new cases. As of June 2, there were 166 HIV cases in Scott County. Of those patients interviewed by the CDC, 96% reported injecting Opana intravenously. I wonder if there are any injured workers among them. And this is being driven by a formulation that Endo claims is abuse-deterrent. Turns out the supposed abuse-deterrence makes it much harder, if not impossible, to crush and snort the drug. As for cooking it down to liquid form and injecting it? Endo hasn't figured that out yet.
The federal government has taken aim at big pharma's painkiller marketing tactics. Purdue Pharma, makers of Oxycontin, paid a $635 million fine in 2007 in connection with a guilty plea for misleading doctors about the abuse potential of the drug. The next year, Cephalon, makers of Actiq, paid a $425 million fine for misleading marketing. That's more than $1 billion in fines in an $8 billion industry... and it just keeps rolling. What do you imagine the gross margin per pill is for Opana (which does $1.16 billion in annual sales)?
Finally, the FDA has proven to be a misguided and inconsistent ally in the fight against prescription drug misuse and abuse. In the midst of an epidemic, they've not hesitated to add new opioids to the market (Zoyhdro and Hysingla come to mind). They've also focused a lot of energy on "abuse-deterrent" formulations of extended release opioids. While they did not grant Opana ER that distinction, I've held the view for some time that abuse-deterrence is necessary, but by itself, entirely insufficient to stem the tide of misuse and abuse of opioids.
We have a long way to go.
Michael
On Twitter @PRIUM1
Yes, the article offers a fairly thorough overview of the recent history of pain management in this country. The usual suspects make their appearances (big pharma, Russell Portenoy, the Joint Commission, etc.) and the standard statistics are rolled out ($8 billion painkiller market, 17,000 annual deaths from overdose, more than 200 million annual prescriptions written for opioids, etc.) You know most of this and it would be easy to scan the article and think (as I usually do), "If Time Magazine is only now publishing a story about the problem, we must be making progress..."
But this article turns out to shine some important light on three issues we normally miss when we contemplate the epidemic of prescription drug misuse and abuse: First, that there are incredibly harmful unintended consequences that no one could have foreseen; second, seemingly harsh punitive measures taken against pharma companies haven't put a dent in the problem; third, the FDA isn't helping.
Perhaps the scariest among many unintended consequences is the one highlighted in this article - the rise of Hepatitis C and HIV infections among intravenous drug users addicted to opioids. In January, Scott County reported an alarming jump in new HIV cases: eight new HIV-positive patients in a small, rural community. By March, there were 81 new cases. As of June 2, there were 166 HIV cases in Scott County. Of those patients interviewed by the CDC, 96% reported injecting Opana intravenously. I wonder if there are any injured workers among them. And this is being driven by a formulation that Endo claims is abuse-deterrent. Turns out the supposed abuse-deterrence makes it much harder, if not impossible, to crush and snort the drug. As for cooking it down to liquid form and injecting it? Endo hasn't figured that out yet.
The federal government has taken aim at big pharma's painkiller marketing tactics. Purdue Pharma, makers of Oxycontin, paid a $635 million fine in 2007 in connection with a guilty plea for misleading doctors about the abuse potential of the drug. The next year, Cephalon, makers of Actiq, paid a $425 million fine for misleading marketing. That's more than $1 billion in fines in an $8 billion industry... and it just keeps rolling. What do you imagine the gross margin per pill is for Opana (which does $1.16 billion in annual sales)?
Finally, the FDA has proven to be a misguided and inconsistent ally in the fight against prescription drug misuse and abuse. In the midst of an epidemic, they've not hesitated to add new opioids to the market (Zoyhdro and Hysingla come to mind). They've also focused a lot of energy on "abuse-deterrent" formulations of extended release opioids. While they did not grant Opana ER that distinction, I've held the view for some time that abuse-deterrence is necessary, but by itself, entirely insufficient to stem the tide of misuse and abuse of opioids.
We have a long way to go.
Michael
On Twitter @PRIUM1
Tuesday, April 21, 2015
The Worst Kind of "Whack-a-Mole"
I've heard the "whack-a-mole" analogy applied to nearly every facet of business. Frankly, it's a tired and worn out analogy. But it's also an image that paints a clear picture of a common issue and, thus, we can't seem to escape its constant use. We're always solving one problem only to create a myriad of unanticipated and unintentional consequences that require ever greater effort to address. Hit one "mole" on the head and another quickly pops up elsewhere to take its place.
Yesterday, the Journal of the American Medical Association released a study that highlights the worst kind of "whack-a-mole" imaginable.
The good news: After the introduction of an abuse deterrent formulation of Oxycontin and the discontinuation of propoxyphene in the latter half of 2010, overall opioid prescriptions appear to have declined 19% vs. where we would have expected them to be. Mind you, that's not a 19% reduction in scripts; rather, it's a 19% reduction vs. a statistical forecast of a line that was trending up.
So where did the next mole pop its head up?
During the same period, there was a 23% increase in heroin overdose.
We can add this to the list of reasons abuse deterrent opioids are not the answer.
The study does not establish a causal link between the reduction in opioid scripts and the increase in heroin overdoses, but this phenomenon has been a recurring theme in various reports and studies across the country for some time now. When Massachusetts Governor Deval Patrick declared a public state of emergency in March of 2014, he cited both prescription opioid abuse and heroin overdoses as grounds for his decision. Is it any wonder that just a week later, Blue Cross Blue Shield of Massachusetts released an 18 month "check up" on its first-in-the-country program requiring pre-authorization for prescription opioids? In it, BCBS brags that, starting in July 2012, they decreased claims for short acting opioids by 20% and long acting opioids by 50%. And yet, the Governor is declaring a state of emergency in early 2014? Could that be due to at least some portion of BCBS members whose Oxycontin was cut off turning to cheap street drugs? Perhaps because the insurer, in an effort to stem the tide of prescription drug spend (instead of prescription drug abuse) failed to address the underlying medical issues faced by its members?
PRIUM's own parent company, Ameritox, produced a very compelling piece of research based on our own data that shows:
Yesterday, the Journal of the American Medical Association released a study that highlights the worst kind of "whack-a-mole" imaginable.
The good news: After the introduction of an abuse deterrent formulation of Oxycontin and the discontinuation of propoxyphene in the latter half of 2010, overall opioid prescriptions appear to have declined 19% vs. where we would have expected them to be. Mind you, that's not a 19% reduction in scripts; rather, it's a 19% reduction vs. a statistical forecast of a line that was trending up.
So where did the next mole pop its head up?
During the same period, there was a 23% increase in heroin overdose.
We can add this to the list of reasons abuse deterrent opioids are not the answer.
The study does not establish a causal link between the reduction in opioid scripts and the increase in heroin overdoses, but this phenomenon has been a recurring theme in various reports and studies across the country for some time now. When Massachusetts Governor Deval Patrick declared a public state of emergency in March of 2014, he cited both prescription opioid abuse and heroin overdoses as grounds for his decision. Is it any wonder that just a week later, Blue Cross Blue Shield of Massachusetts released an 18 month "check up" on its first-in-the-country program requiring pre-authorization for prescription opioids? In it, BCBS brags that, starting in July 2012, they decreased claims for short acting opioids by 20% and long acting opioids by 50%. And yet, the Governor is declaring a state of emergency in early 2014? Could that be due to at least some portion of BCBS members whose Oxycontin was cut off turning to cheap street drugs? Perhaps because the insurer, in an effort to stem the tide of prescription drug spend (instead of prescription drug abuse) failed to address the underlying medical issues faced by its members?
PRIUM's own parent company, Ameritox, produced a very compelling piece of research based on our own data that shows:
- 4 out of 5 heroin users abused prescription drugs first
- 56% of the time, in heroin positive samples, the opioid prescribed to the patient was not found
- 66% of heroin users abused both heroin and prescription painkillers in the last month
The most cynical among us in workers' compensation will think (though never say publicly), "Fine with me. I'm not paying for heroin and I can either settle or cease benefits on this claim with relative ease."
Those of you that care about injured workers will see this data for what it really is - a warning. A warning that we must be careful and measured and caring in our approach to issues of prescription drug misuse and abuse in workers' compensation.
We haven't really solved a problem until we've addressed the underlying issues of dependence and addiction.
Michael
Follow us on Twitter @PRIUM1
Follow us on Twitter @PRIUM1
Wednesday, February 11, 2015
Non-medical Use and Addiction: Distinctions in the Opioid Crisis
A new study coming out soon in the Annual Review of Public Health attempts to reframe our discussion regarding the opioid crisis. Often, we focus attention on nonmedical use of opioids. Those of us in the insurance world know that while nonmedical use is a serious societal issue, it's only one part of the opioid problem.
From the study (among the authors of which is Andrew Kolodny, one of the most well known and recognized voices of reason in the public dialogue around the opioid crisis):
"Policy makers and the media often characterize the opioid crisis as a problem of nonmedical opioid pain reliever abuse by adolescents and young adults. However, several lines of evidence suggest that addiction occurring in both medical and nonmedical users, rather than abuse per se, is the key driver of opioid-related morbidity and mortality in medical and nonmedical opioid pain reliever users."
This distinction is critical because it focuses our attention, our resources, and our solutions in a different direction (or, at least, in more directions) than if we were to simply assume that opioid overdose deaths are driven by diversion, misuse, and abuse among young people.
The reality is that there are likely as many as 5 million people in this country addicted to prescription opioids and as many as half of them are receiving legitimate prescriptions from legitimate doctors for legitimate pain. Not all chronic pain patients on long term opioid therapy will exhibit drug seeking or otherwise aberrant behavior.
Another important insight from the paper is the analogy that Dr. Kolodny and his colleagues draw between the methods of combating other public health crises and the approach we should consider taking toward the opioid crisis:
"... our purposes is to demonstrate that prevention strategies employed in epidemiologic responses to communicable and noncommunicable disease epidemics apply equally well when the disease in question is opioid addiction. Interventions should focus on preventing new cases of opioid addiction (primary prevention), identifying early cases of opioid addiction (secondary prevention), and ensuring access to effective addiction treatment (tertiary prevention)."
We have a long way to go in all three categories, but papers like this push our collective thinking in the right direction. Worth a read.
Michael
On Twitter @PRIUM1
From the study (among the authors of which is Andrew Kolodny, one of the most well known and recognized voices of reason in the public dialogue around the opioid crisis):
"Policy makers and the media often characterize the opioid crisis as a problem of nonmedical opioid pain reliever abuse by adolescents and young adults. However, several lines of evidence suggest that addiction occurring in both medical and nonmedical users, rather than abuse per se, is the key driver of opioid-related morbidity and mortality in medical and nonmedical opioid pain reliever users."
This distinction is critical because it focuses our attention, our resources, and our solutions in a different direction (or, at least, in more directions) than if we were to simply assume that opioid overdose deaths are driven by diversion, misuse, and abuse among young people.
The reality is that there are likely as many as 5 million people in this country addicted to prescription opioids and as many as half of them are receiving legitimate prescriptions from legitimate doctors for legitimate pain. Not all chronic pain patients on long term opioid therapy will exhibit drug seeking or otherwise aberrant behavior.
Another important insight from the paper is the analogy that Dr. Kolodny and his colleagues draw between the methods of combating other public health crises and the approach we should consider taking toward the opioid crisis:
"... our purposes is to demonstrate that prevention strategies employed in epidemiologic responses to communicable and noncommunicable disease epidemics apply equally well when the disease in question is opioid addiction. Interventions should focus on preventing new cases of opioid addiction (primary prevention), identifying early cases of opioid addiction (secondary prevention), and ensuring access to effective addiction treatment (tertiary prevention)."
We have a long way to go in all three categories, but papers like this push our collective thinking in the right direction. Worth a read.
Michael
On Twitter @PRIUM1
Subscribe to:
Posts (Atom)